Pharma Deals Review, Vol 2007, No 86 (2007)

Font Size:  Small  Medium  Large

ARIAD and Merck & Co. Enter into Global Co-Development Deal

Business Review Editor

Abstract


ARIAD Pharmaceuticals entered into a co-development deal worth a potential US$1.127 B with Merck & Co to develop/commercialize AP23573, ARIAD’s novel mTOR inhibitor for use in cancer.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.